Please use this identifier to cite or link to this item:
|Title:||Androgens and prostate cancer; pathogenesis and deprivation therapy.|
|Authors:||Grossmann, Mathis;Cheung, Ada S;Zajac, Jeffrey D|
|Affiliation:||Dept. of Medicine, Austin Health, University of Melbourne, Victoria, Australia; Dept. of Endocrinology, Austin Health, Victoria, Australia. Electronic address: firstname.lastname@example.org.|
|Citation:||Best Practice & Research. Clinical Endocrinology & Metabolism 2013; 27(4): 603-16|
|Abstract:||Although androgen receptor signaling is critical for prostate cancer growth and survival, evidence supporting a favorable risk-benefit ratio of androgen deprivation therapy (ADT) is currently limited to men with high-risk or metastatic disease. This is in part because ADT has been associated with a number of constitutional and somatic side effects, consistent with the widespread tissue expression of sex steroid receptors. ADT is the most common contemporary cause of severe hypogonadism, and men receiving this therapy represent a unique model of severe sex steroid deficiency with a defined time of onset. This review will present an update on the role of ADT in the treatment of prostate cancer, will summarize recent evidence regarding ADT-associated adverse effects with particular emphasis on cardiometabolic and musculoskeletal health, and will provide recommendations for further research.|
|Internal ID Number:||24054933|
|Subjects:||androgen deprivation therapy|
Androgen Antagonists.adverse effects.therapeutic use
Bone Resorption.chemically induced
Prostatic Neoplasms.drug therapy.epidemiology
Receptors, Androgen.drug effects
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.